Asset
INSULIN DEGLUDEC
Revenue
No revenue reported in loaded filings.
Clinical trials (114)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02501161 | phase3 | completed | 2016-01-31 | 2018-10-03 | Novo Nordisk A/S | A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus |
| NCT01713530 | phase3 | completed | 2013-02-21 | 2014-01-09 | Novo Nordisk A/S | A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin |
| NCT02906917 | phase3 | completed | 2016-09-20 | 2017-08-31 | Novo Nordisk A/S | A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification |
| NCT02420262 | phase3 | completed | 2015-07-26 | 2016-10-05 | Novo Nordisk A/S | A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus |
| NCT02298192 | phase3 | completed | 2014-11-21 | 2015-12-23 | Novo Nordisk A/S | A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms |
FDA applications (3)
| Application | Type | Applicant |
|---|---|---|
| BLA 203313 | BLA | Novo Nordisk Inc. |
| BLA 203314 | BLA | Novo Nordisk Inc. |
| BLA 208583 | BLA | Novo Nordisk Inc. |
Marketed products (5)
- RYZODEG 70/30
- TRESIBA
- TRESIBA
- TRESIBA
- XULTOPHY 100/3.6